Trials 29
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-11-05 | Takeda | Results Takeda Announces Topline Secondary Endpoint Results from the Phase 3 TRINOVA-1 Trial of Trebananib (AMG 386) for Recurrent Ovarian Cancer takeda.com ↗
The study results did not demonstrate a statistically significant improvement in OS. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-11-05 | Takeda | Takeda Announces Topline Secondary Endpoint Results from the Phase 3 TRINOVA-1 Trial of Trebananib (AMG 386) for Recurrent Ovarian Cancer takeda.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 34 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trebananib | “Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2...” PMID 25747197 ↗ Mar 201513“A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.” PMID 23361051 ↗ Jan 2013 “A phase 1b, open-label study of trebananib in combination with paclitaxel and” PMID 25037684 ↗ Jul 2014 “AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)” NCT01281254 ↗ |
| Known as | AMG 386 | “To estimate the proportion of patients with persistent or recurrent endometrial cancer, who survive progression-free for at least 6 months and the proportion of patients who...” NCT01210222 ↗22“Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2...” PMID 25747197 ↗ Mar 2015 “A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.” PMID 23361051 ↗ Jan 2013 “The drug being tested in this study is called trebananib (AMG 386).” NCT02525536 ↗ “AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)” NCT01281254 ↗ |
| Action | Inhibit | “neutralizes the interaction of angiopoietin-1 and angiopoietin-2 with Tie2” PMID 22692704 ↗ Jun 2012 |
| Modality | Peptide | “AMG 386, a peptibody (a peptide Fc fusion)” PMID 22692704 ↗ Jun 2012 |
| Route | Intravenous | “after intravenous administration” NCT00102830 ↗ |
| Target | ANGPT1 | “Angiopoietin-1 inhibitor” CHEMBL2108568 ↗ |
| Target | ANGPT2 | “Angiopoietin-2 inhibitor” CHEMBL2108568 ↗ |